Research News
View articles by month and year
-
About 25% of Women Either Don’t Start or Don’t Finish Hormonal Therapy
A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don’t start taking the medicine or stop taking it early.
-
Fareston Is Effective Against Some Advanced-Stage Cancers That Have Stopped Responding to Aromatase Inhibitors
A small study has found that Fareston is a good treatment option for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive breast cancer that grew while being treated with the aromatase inhibitors Arimidex or Femara.
-
Combination of Arimidex and Faslodex Better Than Arimidex Alone to Treat Metastatic Breast Cancer
A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived about 6 months longer than women treated only with Arimidex.
-
Aromatase Inhibitors Seem Less Effective in Obese Women
A small study found that while obese women diagnosed with early-stage, hormone-receptor-positive breast cancer who took Arimidex and Femara had lower estrogen levels than before they started treatment, their estrogen levels were still more than double those of women at a healthy weight.
-
Arimidex-Faslodex Combo Improves Survival in Metastatic Breast Cancer
A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived 6 months longer than women treated only with Arimidex.
-
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Zometa Plus Hormonal Therapy Reduces Recurrence Risk
A study has found that Zometa and hormonal therapy after surgery could reduce the risk of the cancer coming back in premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer better than hormonal therapy alone.
-
Arimidex and Aromasin Equally Good at Reducing Recurrence Risk
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Aromatase Inhibitors Increase Risk of Heart Problems
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
